GlpBio

JAK

Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.

JAK 相关产品(149)

  • GC15980 structure
    GC15980WP1066
    CAS: 857064-38-1
    纯度: >99.50%

    WP1066是一种STAT3（信号转导和转录激活因子3）可逆的竞争性抑制剂，针对STAT3 Tyr705位点磷酸化的抑制IC 50 约为2.5μM，通常用于恶性肿瘤及炎症相关疾病的研究。

  • GC16124 structure
    GC16124Ruxolitinib phosphate
    CAS: 1092939-17-7
    纯度: >99.50%

    A potent and selective JAK1/JAK2 inhibitor

  • GC16468 structure
    GC16468CYT387 sulfate salt
    CAS: 1056636-06-6
    纯度: >98.00%

    A potent inhibitor of JAK1 and JAK2

  • GC16584 structure
    GC16584TCS 21311
    CAS: 1260181-14-3
    纯度: >95.00%

    A JAK3 inhibitor

  • GC16828 structure
    GC16828Tofacitinib (CP-690550,Tasocitinib)
    CAS: 477600-75-2
    纯度: >98.00%

    Tofacitinib (CP-690550,Tasocitinib)是一种Janus激酶（JAK）抑制剂，用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎、多关节病程青少年特发性关节炎和溃疡性结肠炎。

  • GC17020 structure
    GC17020S-Ruxolitinib (INCB018424)
    CAS: 941685-37-6
    纯度: >99.50%

    鲁索替尼 S 对映体是鲁索替尼的 S 对映体。鲁索替尼 S 对映异构体是一种 JAK 抑制剂

  • GC17033 structure
    GC17033Lestaurtinib
    CAS: 111358-88-4
    纯度: >98.00%

    A potent JAK2 and PRK1 kinase inhibitor

  • GC17050 structure
    GC17050CYT387
    CAS: 1056634-68-4
    纯度: >98.50%

    A potent inhibitor of JAK1 and JAK2

  • GC17055 structure
    GC170551,2,3,4,5,6-Hexabromocyclohexane
    CAS: 1837-91-8

    1,2,3,4,5,6-六溴环己烷（1,2,3,4,5,6-Hexabromocyclohexane）直接抑制JAK2激酶结构域内的口袋，抑制自身磷酸化。

  • GC17762 structure
    GC17762NSC 33994
    CAS: 82058-16-0

    NSC 33994 (G6) 是一种选择性 JAK2 抑制剂，IC50 为 60 nM。

  • GC19408 structure
    GC19408FM381
    CAS: 2226521-65-7
    纯度: >98.00%

    A potent JAK3 inhibitor

  • GC10341 structure
    GC10341Peficitinb (ASP015K, JNJ-54781532)
    CAS: 944118-01-8
    纯度: >98.00%

    A JAK inhibitor

  • GC10638 structure
    GC10638AT9283
    CAS: 896466-04-9
    纯度: >99.50%

    A broad spectrum kinase inhibitor

  • GC11209 structure
    GC11209Cerdulatinib (PRT062070)
    CAS: 1198300-79-6
    纯度: >99.50%

    A dual inhibitor of Syk and JAKs

  • GC11652 structure
    GC11652CHZ868
    CAS: 1895895-38-1
    纯度: >99.00%

    CHZ868 是一种 II 型 JAK2 抑制剂，在 EPOR JAK2 WT Ba/F3 细胞中的 IC50 为 0.17 μM。

  • GC13229 structure
    GC13229NVP-BSK805
    CAS: 1092499-93-8

    A potent, selective JAK2 inhibitor

  • GC14857 structure
    GC14857LFM-A13
    CAS: 244240-24-2
    纯度: >99.50%

    A BTK inhibitor

  • GC14938 structure
    GC14938PF-03394197(Oclacitinib)
    CAS: 1208319-26-9

    A JAK family kinase inhibitor

  • GC16875 structure
    GC16875FLLL32
    CAS: 1226895-15-3
    纯度: >99.50%

    An inhibitor of JAK2/STAT3 signaling

  • GC17586 structure
    GC17586Tofacitinib (CP-690550) Citrate
    CAS: 540737-29-9
    纯度: >99.50%

    A pan-JAK inhibitor

  • GC19204 structure
    GC19204Itacitinib
    CAS: 1334298-90-6
    纯度: >99.50%

    Itacitinib是一种JAK1抑制剂（IC 50 =2nM），Itacitinib可通过选择性抑制JAK1酪氨酸激酶以调节JAK-STAT信号通路，同时通过减少促炎细胞因子的产生以调控免疫反应。

  • GC19288 structure
    GC19288PF-06651600
    CAS: 1792180-81-4
    纯度: >99.50%

    PF-06651600 (PF-06651600) 是一种具有口服活性的选择性 JAK3 抑制剂，IC50 为 33.1 nM。

  • GC19320 structure
    GC19320SAR-20347
    CAS: 1450881-55-6
    纯度: >98.00%

    A JAK family kinase inhibitor

  • GC19334 structure
    GC19334Solcitinib
    CAS: 1206163-45-2
    纯度: >99.50%

    A JAK1 inhibitor